CD19+ Chimeric antigen receptor (CAR) T-cells are used against CD19+ hematologic malignancies, such as high-grade B-cell lymphoma and acute lymphoblastic leukemia. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.